PROF · Desk conversation

The broad tape is leaning cautious: the S&P 500, Nasdaq 100, and Russell 2000 were lower at the sealed snapshot. VIX, the market's volatility gauge, rose 1.92% to 15.37; the 10-year yield eased 1.20 basis points to 5.26%. That is pressure across benchmarks, not an explanation for any one company.

The separate breadth proxy leaned negative within its covered sample, but there is no end-of-day breadth reading. We can describe that sample; we cannot call it a full-market closing count.

The supplied news cut also reports inflation risk in the Fed minutes, repeated payroll revisions, and mixed jobless claims. Gold and oil were higher. Useful backdrop, but none of those items is a company catalyst for the names in this docket.

Profound Medical is my Try of the Day. Its SEC filing gives a preliminary Q3 revenue range of $9.8 million to $10.0 million, and the market response has a separate 20-session relative record behind it. That is a company-specific question with something observable to test.

The linked record is up 15.56% on 17.23 times its three-month average volume. It is above VWAP—the session's volume-weighted average price—so it is trading above the average price paid across the day's volume. That supports the response, not a 15-session forecast.

I would call it Raw Try. The model's S15 positive-return estimate is 42.00% with eight comparable cases. Its modeled largest adverse move has a 15.00% median and a 33.20% lower-tail estimate from entry. Those figures are not certainties, but they make the path risk hard to wave away.

One boundary on that model language: the adverse-move measure tracks the largest modeled fall from the entry reference by the stated horizon; it is not a prediction that the stock will fall that far. The return quantiles are widely spread, and the supplied SEC financial snapshot predates this announcement.

The older snapshot still matters as context: for the quarter ended March 31, it reports a $7.053 million net loss and $8.583 million of operating cash outflow. The new revenue range does not tell us whether the company is profitable.

Agreed on profitability. But the event is not just a headline attached to a moving ticker: the company filing supports the preliminary range, and the 20-session record shows PROF ahead of its healthcare ETF by 9.14 percentage points.

That relative record changes my reading. The 42% estimate is based on only eight comparable cases, while the S15 modeled return quantiles run from -24.80% at P10 to +25.50% at P90, with a negative median. I will support Try because the company disclosure and independent relative behavior are stronger evidence than a single-session spike, but the adverse tail stays live.

I support Try with that reservation. The company filing establishes a preliminary revenue range; it does not establish final results. The PROF dossier has one provider trajectory point, so the next observations must test persistence rather than assume it.

I support Try. The useful point is the combination: the company gave us a fresh result to check, and the stock had already outperformed its healthcare group over twenty sessions. If that relative behavior fades, the case loses its support.

I remain at Raw Try. The thesis is testable, but the prepared financial snapshot still records losses and cash outflow, and the modeled downside is large. I am not persuaded that the full 15-session path clears Try today.

Reopen: The preliminary revenue update and recent relative strength support a testable case, but they do not settle the strongest 15-session path. Please reconsider the comparison with Medtronic and clarify why Profound Medical’s stronger relative record outweighs the unresolved profitability, persistence, and downside risks.

I’m correcting our earlier reasoning. We called Profound’s event and session response the strongest combined case, but that does not settle the 15-session question. The Try of the Day test asks whether the full path is defensible.

The Medtronic comparison is material. Profound’s active model estimates a 42.00% chance of a positive return by session fifteen from eight comparable cases. That estimate comes with a -3.84% median modeled return and a -33.24% P10 adverse excursion. An adverse excursion is the largest modeled dip from the entry reference by that horizon; the tail is not a worst-case limit.

The separate audit-only dispersion result must stay separate from those active model quantiles. It has eight cases and a wide H15 range, with a -2.52% median and +60.48% P90. Neither range is a settled forecast. MDT’s active estimate is more favorable, but its eight-case sample is also small.

Profound’s 20-session performance exceeded XLV by 9.14 percentage points, and the company filed a preliminary Q3 revenue range. That gives us a concrete check. MDT’s relative record was weaker by 4.49 percentage points versus XLV, and we still do not know the exchange-ratio economics. I think Profound’s company update can still support Try of the Day.

The relative record is backward-looking. It does not resolve whether the preliminary revenue becomes profitable revenue, and the prepared financial snapshot predates that update. The active downside and the Medtronic comparison are central, not minor caveats. I support keeping Profound as a research case but downgrading it to Raw Try.

Agreed. The evidence does not justify saying Profound’s stronger relative record outweighs its unresolved profitability, persistence, and downside risks. Its filed update still gives us a useful next check, so the candidate stays selected as Raw Try.

I support Raw Try. A strong day and a company update are facts worth following; neither proves a durable path across fifteen trading sessions.

I also support Raw Try. The model comparisons are bounded context, not certainty, but they expose a countercase the initial decision did not resolve. Four of us support the correction; Marcus dissents and would retain Try of the Day.